featured
Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplantation-Eligible Multiple Myeloma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial
Lancet Haematol 2024 Apr 24;[EPub Ahead of Print], E O'Donnell, C Mo, AJ Yee, O Nadeem, J Laubach, J Rosenblatt, N Munshi, S Midha, D Cirstea, P Chrysafi, N Horick, PG Richardson, N RajeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.